CATL’s 6.7 per cent discount to its Shenzhen-traded shares is much lower than the average 25 per cent discount for ...

Pfizer and RemeGen's HER2 antibody-drug conjugate delivered positive phase 3 results in a bladder cancer trial in China. | ...

The CEOs of JPMorgan and Bank of America are resisting a demand by US lawmakers to withdraw from underwriting this week’s $4 ...

Chinese AI drug developer METiS Pharmaceuticals is preparing for a Hong Kong initial public offering that could raise up to $200 million, highlighting the ongoing surge of investment in artificial ...

The China-based casual dining brand began trading its IPO after pricing its 168,364,000 shares at HKD 7.19 per share.

Minority owner Partners Group say the IPO proceeds will be used to further grow the Hangzhou-headquartered restaurant's ...

Chinese biotech company Bliss Biopharmaceutical (BlissBio) is reportedly considering a Hong Kong initial public offering (IPO ...

Shares of the restaurant chain began trading at HK$7.19 per share, unchanged from the offer price, before plunging 7 per cent ...

Now, with tensions easing and the US$43.6 billion ($56.62 billion) raised in 2025 IPOs so far running just behind the same ...

SINGAPORE] Singapore biotech start-up Mirxes launched its initial public offering (IPO) in Hong Kong on Thursday (May 15) as ...

Trading in the shares is expected to start on May 23. Read more at straitstimes.com. Read more at straitstimes.com.

Jiangsu Hengrui Pharmaceuticals is planning to raise as much as US$1.27 billion via an initial public offering in Hong Kong, joining a wave of Chinese companies seeking to tap the city's market.